JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

Amalgamation of Artificial Intelligence and Traditional Indian Medicine for Sensitization of Benign Prostatic Hyperplasia in Public Health

Neerja R. Sharma, Chandra Shekhar Kaushik
BAMS MD PHD, BAMS MD
Shri Dhanwantri Ayurvedic College Chandigarh
Chief Medical Officer (NFSG), MCD New Delhi

Abstract: -
Amalgamation of Artificial Intelligence (AI) and Traditional Indian Medicine (TIM) presents a novel approach to addressing Benign Prostatic Hyperplasia (BPH) within the realm of public health. BPH is a common condition more among aged men that involves hyperplasia of the prostate, causing urinary complications and significantly impacting the quality of life. Early detection and management are pivotal in mitigating severe health outcomes. Traditional Indian Medicine, particularly Ayurveda, offers a range of natural remedies, including herbal treatments, dietary and lifestyle modifications, and holistic practices such as yoga and meditation, aimed at managing BPH symptoms.

AI enhances the efficacy of TIM through advanced data analytics, predictive modelling, and personalized healthcare solutions. Predictive analytics can utilize patient medical histories and lifestyle to identify, assist, and sensitize those groups who are more prone to developing Benign Prostatic Hyperplasia or those who are under treatment, facilitating early intervention. Diagnostic tools powered by machine learning algorithms can analyze clinical symptoms and medical imaging to assist in accurate and timely diagnosis. Furthermore, AI can customize TIM treatments to fit the unique health profiles of patients, ensuring a personalized approach that maximizes therapeutic outcomes.

Continuous monitoring and follow-up care are critical for managing BPH effectively. AI-driven mobile applications and wearable devices can track patient symptoms, treatment adherence, and lifestyle factors in real-time. This continuous data collection allows for dynamic adjustments to treatment plans and provides healthcare providers with actionable insights into patient progress. By integrating AI's predictive and analytical capabilities with the holistic, patient-centred approach of TIM, this combined methodology can enhance the overall management of BPH, promoting better health outcomes and improving patients' quality of life.

The conglomeration of Artificial Intelligence and TIM conforms a significant advancement in public health strategies for BPH. It leverages the strengths of modern technology and traditional practices to offer a comprehensive, effective, and personalized approach to healthcare. This synergy encourages the sensitization and early detection of BPH and also paves the way for innovative treatment methodologies that can be adapted to various other health conditions.

Keywords: -
AI in Public Health, Technology Integration for Benign Prostatic Hyperplasia Awareness, Sensitization of Benign Prostatic Hyperplasia, Artificial Intelligence in Benign Prostatic Hyperplasia Diagnosis, Traditional Indian Medicine for Benign Prostatic Hyperplasia Education.

Introduction: -

Benign prostatic hyperplasia (Benign Prostatic Hyperplasia) is a prevalent indisposition often observed in elderly men and frequently results in Lower Urinary Tract Symptoms (LUTS). Benign Prostatic Hyperplasia denotes the non-malignant growth or hyperplasia of prostate tissue.[1] Research indicates that its occurrence tends to rise with increasing age. Various non-modifiable and modifiable factors contribute to the development of Benign Prostatic Hyperplasia, including diabetes, diet, genetic factors, localized inflammation, obesity, and metabolic syndrome.[2] Patients with Benign Prostatic Hyperplasia needs to get it the dangers of illness movement some time recently committing to treatment choices and ought to be guided to make any educated decision.[3] Generous prostatic hyperplasia can lead to side effects that have an impact on urine flow. These symptoms include reduced or weak urine flow, nighttime urination, the sensation of not completely emptying the bladder, frequent interruptions during urination, difficulty starting urination, or the need to strain to pass urine, dribbling at the end of urination, a frequent urge and urgent need to urinate, pain during urination or ejaculation. If left untreated, complications such as the development of bladder stones, bladder infections, kidney damage due to backpressure, presence of blood or pus in the urine, experiencing pain in the lower abdomen or genital area during urination, inability to urinate, chills or fever during urination may occur. In severe cases, kidney damage, the development of chronic kidney disease, and renal failure are also possible. Erectile dysfunction, loss of libido, and ejaculatory disorders may be among the accompanying side effects, significantly impacting the individual's mental well-being.[4]

In Ayurveda, Vatasthila is term used to denote condition similar to Benign Prostatic Hyperplasia, a prostatic hypertrophy condition. The symptoms of this condition include distention of the rectum and bladder, blockage of the passage of faeces, urine, and flatus, intense pain, a hard, stony enlargement or gland beneath the navel, and an upwardly extended, conspicuous gland in the navel.[5]

Artificial intelligence (AI) holds significant disruptive potential within the realm of computer science, poised to revolutionize the landscape of medicine and healthcare delivery. Healthcare systems worldwide are encountering major challenges in striving to achieve the 'quadruple aim' for healthcare. [6-8] These challenges encompass enhancing population health, elevating the patient's care experience, improving caregiver satisfaction, and curbing the escalating cost of care. The combination of aging populations, the mounting burden of chronic illnesses, and the increasing expenses of healthcare globally are compelling governments, payers, regulators, and providers to explore innovative and transformative healthcare delivery models. Moreover, amid the current global pandemic, healthcare systems not only face the demand to deliver effective, high-quality care but also to revolutionize care on a large scale by leveraging real-world data-driven insights directly into patient care. Additionally, the pandemic has shed light on shortages in the healthcare workforce and disparities in access to care, issues previously acknowledged by The King's Fund and the World Health Organization. [9-10]

AI has the potential to revolutionize healthcare by making connected and AI-augmented care, precision diagnostics, precision therapeutics, and precision medicine more accessible and standardized. Research in AI applications for healthcare is rapidly progressing, with demonstrations of its potential use in various areas, including drug discovery, virtual clinical consultations, disease diagnosis, prognosis, medication management, and health monitoring.[11]

Material and Methods: -

This review article was constructed by doing a critical examination of the classical Ayurvedic texts, the scientific literature of the present day, and the recent technological developments. The main sources were the ancient Ayurvedic treatises like Charaka Samhita, Sushruta Samhita, and Ashtanga Hridaya that mostly provided foundational information on concepts and terminologies based on Ayurveda and linked directly to the topic under study. Secondary sources included peer-reviewed journals, books, and conference proceedings, which made a discussion of integrating Ayurveda with the modern medical and technological approach.

The present review utilized a systematic search approach on electronic databases like PubMed, Scopus, Google Scholar, and other platforms suggested by AYUSH. Keywords used to obtain literature included "Ayurveda,"

"Traditional Indian Medicine," "Benign Prostatic Hyperplasia," "Vatasthila," "Artificial Intelligence," and "Technology Integration." Both qualitative and quantitative studies have been included to provide maximum coverage.

The inclusion criteria were set with preference to articles that used Ayurveda's traditional perspectives, AI applications in healthcare, and integrative approaches to disease management. Only studies in English, which were also available for full-text access, were considered. Non-peer-reviewed sources, articles without clear methodological approach, and unrelated subjects were excluded.

The data collected was intensively analysed to identify the emerging patterns, gaps, and opportunities for synergy between traditional Ayurvedic practices and modern technological frameworks. Concerning ethical considerations like proper citation and acknowledgment of original sources, the review process remained strict. This methodological framework ensured that knowledge was synthesized in a balanced and evidence-based holistic manner to advance Ayurveda in modern health paradigms.

Result and Discussion: -

The role of AI in healthcare

AI systems are yet not able to think as physicians do [12]. Instead, AI functions similarly to a signal translator by interpreting patterns found in datasets. AI technologies are being used by healthcare companies these days to automate time-consuming, repetitive processes that are tedious. Furthermore, a great deal of effort has been put into demonstrating how AI may be utilized for precision diagnosis (e.g., diabetic retinopathy and radiotherapy planning).

Artificial intelligence (AI) has been a major influence in various industries in recent years, with healthcare being one of the most significant.[13] The implementation of artificial intelligence in medical facilities signifies a fundamental change in the approach to providing and overseeing healthcare services. In order to better understand how artificial intelligence (AI) might support the diagnosis, treatment, and management of benign prostatic hyperplasia, this study will concentrate on clinical decision-making, management, diagnostics, patient care, and ethical aspects. AI is not widely applied in the administration of healthcare. This has its roots in the early days of computers, when scientists initially proposed the idea of creating robots that could replicate human intelligence.[14] But only with improvements in machine learning methods [15], a rise in processing power, and the accessibility of data [16], AI applications in healthcare began to grow. Significant turning points in this research have been reached, ranging from the earliest expert systems [17] to sophisticated neural networks that can execute some jobs better than human experts.[18] AI is being used in health in a wide range of ways nowadays.[19] It helps with illness diagnosis, prognosticating patient outcomes, and adjusting therapy regimens in clinical settings.[20] Artificial Intelligence (AI) enhances patient flow and coordination, optimizes procedures, and increases operational efficiency in hospital administration. AI enhances the precision and speed of image processing in radiology and pathology, which is useful in the field of medical diagnostics.[21] Additionally, AI transforms the paradigm of patient-physician contact and plays a significant role in patient care through virtual support, telemedicine, and remote monitoring.[22]

Knowledge of traditional Indian medicine in Benign Prostatic Hyperplasia

All Ayurvedic texts describe the different mutra-rogas and their management covering most pathology of urinary system. Acharya Sushruta mentions 12 types of Mutraghata [23] and Acharya Charaka mentions 13 types of Mutraghata.[24] In other words, "mutra" means urine and "aghata" means urinary pathology. Urinary retention and pain in the suprapubic region, the main features of Mutraghata, can be seen due to outlet obstruction and may be linked to Benign Prostatic Hyperplasia on this basis. Vatasthila and mutragranthi are mentioned under Mutraghata, according to its symptoms, which are very similar to obstructive uropathy due to enlarged prostate. Vatasthila is a disease in which the Apana Vayu is disturbed and the gland becomes swollen, palpable and very painful, which hinders the flow of urine. [25,26,27] Mutra-granthi is a condition in which a small, round, permanent glandular edema appears suddenly, the Vasti Mukha, resulting in the sudden appearance. Obstruction of urine causes symptoms similar to Ashmari.[28] Therefore, Benign Prostatic Hyperplasia is closely related to Vatasthila in terms of symptoms and complications.

Acharyas have not mentioned any specific factors that cause Mutraghata, but these factors that cause mootrakricchra can be considered.[29]

1. Ativyayama – excessive exercise
2. Tikshna aushadha – strong potency drugs

3. Rukshamadya prasanga – excessive indulgence in alcohol.
4. Nityadrutaprishtayaanat – riding on the back of expeditious animals
5. Anupamatsya – intake of flesh of wet land animals.
6. Adhyashana – intake of food without proper digestion of previous meal.
7. Ajeerna – indigestion.

In addition to the above factors, the aetiology of mootravaha srotodushti is also to be taken into consideration, which is described by Acharya Charaka in Vimana Sthana as below –

1. Mootratodaka bhakshya – excessive water intake
2. Stree sevanat – indulging in sex
3. Mootranigrahat – suppression of micturition urge
4. Ksheena – emaciated person
5. Abhikshat – trauma to urinary passage.

Mootravaha srotasa disorders similar to description of urological disorders in modern language are well described in Ayurvedic literature. Acharyas mentioned various diseases of different srotasas including mootravaha srotasa and many diseases have many similarities with the description of modern diseases like mootraghata with Benign Prostatic Hyperplasia, ashmaree with urinary stones, mootra krichchhra with urinary infection etc. Modern times develop and innovate so fast that it can address the medical needs of society and tries to treat diseases holistically. Therefore, based on the needs of the 21st century and the world, it is extremely necessary to apply the principles of long-term care of Ayurveda. Hence evaluation of terminology, diseases and their management described in Ayurveda is very necessary for proper evaluation and correlation in the interest of the society. Of all the Mootravaha Srotas diseases, 12 or 13 types of Mutraghata are mentioned in the Samhitas.[29]

Benign Prostatic Hyperplasia

A major cause of lower urinary tract symptoms (LUTS) in older men is benign prostatic hyperplasia, which is a benign development or expansion of prostate tissue. It has been demonstrated that the condition worsens with age. Benign prostatic hyperplasia is 50% to 60% more common in males over 60 at autopsy, and rises to 80% to 90% in those over 70.[30] The term Benign Prostatic Hyperplasia has been defined in a variety of ways in the literature. LUTS, benign prostatic hyperplasia, and prostate cancer prevention are a few of them (BPE). Premenstrual syndrome is referred to as benign prostatic hyperplasia, whereas benign prostatic enlargement, or BPE, is an enlarged prostate that is often due to benign prostatic hyperplasia and is also known as bladder outlet blockage or urine flow obstruction. [31, 32] Mild prostatic obstruction is a bladder outlet blockage seen in patients with BPE.[33] LUTS refers to abnormalities of the urine, mainly benign prostatic hyperplasia, that are observed in cancer and prostate-related disorders. The word "prostatitis" was superseded by this one. The proliferation of stromal and epithelial cells in the prostatic transition zone around the urethra is a hallmark of the development of benign prostatic hyperplasia. Urinary retention, incontinence, and LUTS symptoms can result from this constriction of the urethra and restriction of urine flow.[34] If untreated, it can result in life-threatening hypertension and irreversible, long-term alterations to the lungs' muscular structure.

Benign prostatic hyperplasia can be treated with a variety of medicinal and surgical techniques as well as attentive waiting. There are two categories of risk factors: modifiable and non-modifiable. Age, heredity, region, and obesity are other variables that affect the development of benign prostatic hyperplasia. [35, 36]

Epidemiology of Benign Prostatic Hyperplasia

Disparities in explication make rendition of population investigations of Benign Prostatic Hyperplasia difficult. For example, Benign Prostatic Hyperplasia stands for histology, prostate size, prostate size, tumor obstruction, or medical diagnosis of Benign Prostatic Hyperplasia. LUTS refers to a range of urinary symptoms associated with prostate or bladder problems or Benign Prostatic Hyperplasia. Age is a significant predictor of Benign Prostatic Hyperplasia and subsequent development of LUTS. Benign prostatic hyperplasia has been demonstrated in 50% of men over 50, and as men age, so does the correlation with the development of LUTS.[37] Studies demonstrating that prostate size rises with age (by 2% to 2.5 percent every year) lend credence to this.[38] A study done in the United States found that prostatic hyperplasia is more common in those over 70 and over 70 years old, with a frequency of 70% among those 60 to 69 years old.[39] In the Boston Area Community Health Survey, the prevalence of LUTS in men rose from 8% in the age range of 30-39 to 35% in the age range of 60-69. According to a different US population-based survey, 56% of males between the ages of 50 and 79 reported benign prostatic

hyperplasia symptoms. [40, 41] Between 1998 and 2007, the number of cases of benign prostatic hyperplasia in the US approximately doubled.[42] The population is predicted to continue to age, rising from 9.3 million in 2003 to 19.5 million in 2030.[43] There will be a rise in symptomatic instances of benign prostatic hyperplasia as the global population ages. Studies conducted worldwide have revealed that people in the West tend to have larger prostates than those in other regions of the world, particularly Southeast Asia.[44] A lower prostate size was not linked to symptoms, according to another study examining the connection between LUTS and prostate volume. However, Indian men were found to have a greater IPSS than Western men.[45]

Integration of Traditional Indian medicine and AI for Benign Prostatic Hyperplasia sensitization

Artificial intelligence can be potentially integrated with Traditional Indian Medicine and modern knowledge of Benign Prostatic Hyperplasia to enhance the reach and engagement for people esp. aged men. This integration can help men for early diagnosis, monitoring of symptoms and progression of disease and treatment. AI-Powered applications with virtual assistants can help in predictive analysis for targeted population. AI can help to improve the outcome in public health.

Role of AI in Benign Prostatic Hyperplasia Management

AI can significantly enhance the understanding, diagnosis, and treatment of Benign Prostatic Hyperplasia by:

Data Analysis: AI can assist to analyse large and complex data of patient records to identify patterns and efficacy of Ayurvedic treatments.[46]

Predictive Modelling: Machine learning algorithms can predict patient outcomes based on various treatment protocols, personalizing treatment plans.[47]

Natural Language Processing (NLP): AI can process and extract valuable information from traditional texts and modern research papers on Ayurveda.[48]

Clinical Decision Support: AI can assist healthcare professionals by providing evidence-based recommendations for integrating Ayurvedic and conventional treatments.[49]

Integrating Traditional Medicine and AI

1. Data Collection: Gather data from Ayurvedic practitioners, clinical studies, and patient outcomes related to Ayurvedic treatments for Benign Prostatic Hyperplasia.[50]
2. Algorithm Development: Develop machine learning models to analyze the efficacy of different Ayurvedic treatments. This could involve supervised learning for outcome prediction and unsupervised learning for identifying hidden patterns in treatment efficacy.[51]
3. Knowledge Base Creation: Use NLP to extract information from Ayurvedic texts and modern scientific literature to build a comprehensive knowledge base.[52]
4. Clinical Decision Support Systems (CDSS): Implement AI-driven CDSS that integrate Ayurvedic and conventional medical knowledge to support healthcare providers in decision-making.[53]
5. Patient Monitoring and Feedback: Use AI to monitor patient responses to treatments and adjust protocols dynamically based on real-time data.[54]

Implementation Steps

1. Collaborative Research: Foster collaboration between Ayurvedic practitioners, data scientists, and medical researchers.
2. Data Standardization: Standardize data collection methods to ensure consistency and accuracy.
3. Pilot Studies: Conduct pilot studies to validate AI models and algorithms with real-world data.
4. Technology Integration: Develop user-friendly platforms for healthcare providers to access AI-driven insights.
5. Regulatory Compliance: To corroborate that AI programme come around with medical regulations and ethical standards.

Potential Benefits

- Personalized Medicine: Tailoring treatments based on individual patient data and predictive analytics.
- Improved Outcomes: Enhanced efficacy of treatments by integrating

Conclusion

The integration of Artificial Intelligence (AI) with Traditional Indian Medicine and modern knowledge of Benign Prostatic Hyperplasia (Benign Prostatic Hyperplasia) presents a promising avenue for revolutionizing Benign Prostatic Hyperplasia management. AI's capabilities in data analysis, predictive modelling, Natural Language Processing (NLP), and clinical decision support can significantly enhance patient outcomes and optimize treatment strategies for this prevalent condition affecting aging men.

Benign Prostatic Hyperplasia is an enlargement of the prostate, commonly causing lower urinary tract symptoms (LUTS) in older males. Benign prostatic hyperplasia is more common in older men worldwide and affects a considerable proportion of them as they age. As the illness progresses, stromal and epithelial cells proliferate in the prostate's transition zone, causing urethral constriction and blockage and a host of urinary symptoms, including LUTS, urine retention, and incontinence. Benign prostatic hyperplasia can result in consequences like high blood pressure and permanent lung muscle alterations if left untreated. Traditional Indian Medicine, particularly Ayurveda, provides valuable insights into urinary system disorders, including Benign Prostatic Hyperplasia. References in Ayurvedic texts describe various urinary pathologies and their management, with similarities drawn between conditions like Vatasthila and Mutragranthi and modern obstructive uropathy due to enlarged prostate. Ayurvedic texts caution against factors like excessive exercise, potent medications, and indigestion that may contribute to urinary disorders, emphasizing the importance of holistic care and lifestyle in maintaining urological health. There is a lot of promise in combining AI with contemporary medical understanding and Ayurvedic concepts to address benign prostatic hyperplasia. Large datasets from clinical trials and patient records may be examined closely to find trends and evaluate the effectiveness of Ayurvedic therapies by utilizing AI's data analysis skills. For those with benign prostatic hyperplasia, machine learning algorithms can forecast patient outcomes based on a variety of treatment regimens, allowing for individualized and optimal care plans.

Furthermore, Benign Prostatic Hyperplasia patients can benefit from early diagnosis, symptom tracking, and therapy progression tracking made easier by AI-driven predictive modeling. This improves patient engagement and results in better health, particularly for older populations. The knowledge base of healthcare practitioners may be enhanced by using Natural Language Processing (NLP) to extract and synthesize information from modern research publications on Benign Prostatic Hyperplasia and Traditional Indian Medicine as well as from old Ayurvedic writings.

AI-enabled Clinical Decision Support Systems (CDSS) can give evidence-based suggestions for combining conventional and Ayurvedic medical treatments, assisting medical professionals in their decision-making. Combining artificial intelligence (AI) technology with conventional medical methods can result in a patient-centered, all-encompassing approach to benign prostatic hyperplasia that breaks down geographical boundaries and fosters a thorough awareness of the problem among the healthcare community worldwide.

To implement this innovative approach effectively, collaborative research efforts involving Ayurvedic practitioners, data scientists, and medical researchers are imperative. Data standardization, pilot studies, technology integration, and regulatory compliance will be key steps in ensuring the efficacy and ethical implementation of AI-driven solutions in Benign Prostatic Hyperplasia management. By personalizing treatment plans, improving overall outcomes, and advancing the field of urology through a blend of ancient wisdom and cutting-edge technology, this integration holds the potential to redefine healthcare standards and enhance the quality of life for individuals grappling with Benign Prostatic Hyperplasia.

References: -

[1] Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005;7 Suppl 9(Suppl 9):S3-S14. [PMC free article] [PubMed]

[2] Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, Woo HH, Te AE, Kaplan SA. Benign prostatic hyperplasia. Nat Rev Dis Primers. 2016 May 05;2:16031. [PubMed]

[3] Ng M, Leslie SW, Baradhi KM. Benign Prostatic Hyperplasia. [Updated 2024 Jan 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK558920/

[4] Suresh K. Prostate health in India (Benign Prostatic Hyperplasia &Prostate Cancer). Arch Cancer Sci Ther. 2022; 6: 009-017.

[5] Charak Samhita New Edition. 1st ed. Jamnagar, Ind: CSRTSDC; 2020. https://www.carakasamhitaonline.com/index.php?title=Vatashthila&oldid=42752. Accessed June 13, 2024.
[6] Berwick DM, Nolan TW, Whittington J. The Triple Aim: Care, health, and cost. *Health Affairs* 2008;27:759–69. [PubMed] [Google Scholar]
[7] Bodenheimer T, Sinsky C. From triple to quadruple aim: care of the patient requires care of the provider. *Ann Fam Med* 2014;12:573–6. [PMC free article] [PubMed] [Google Scholar]
[8] Feeley D. *The Triple Aim or the Quadruple Aim? Four Points to Help Set Your Strategy*. Institute for Healthcare Improvement, 2017. www.ihi.org/communities/blogs/the-triple-aim-or-the-quadruple-aim-four-points-to-help-set-your-strategy. [Google Scholar]
[9] The Health Foundation, Nuffield Trust, The King's Fund . *The health care workforce in England: make or break?* The King's Fund, 2018. [Google Scholar]
[10] World Health Organization. *Working for health and growth: Investing in the health workforce*. WHO, 2016. http://apps.who.int/iris/bitstream/10665/250047/1/9789241511308-eng.pdf [Accessed 31 January 2020]. [Google Scholar]
[11] Nachev P, Herron D, McNally N, Rees G, Williams B. Redefining the research hospital. *NPJ Digit Med* 2019;2:119. [PMC free article] [PubMed] [Google Scholar]
[12] Quinn TP, Senadeera M, Jacobs S, Coghlan S, Le V. Trust and medical AI: the challenges we face and the expertise needed to overcome them. *J Am Med Inform Assoc* 2021;28:890–4. [PMC free article] [PubMed] [Google Scholar]
[13] Rajpurkar P., Chen E., Banerjee O., Topol E.J. AI in health and medicine. *Nat. Med.* 2022;28:31–38. doi: 10.1038/s41591-021-01614-0. [PubMed] [CrossRef] [Google Scholar]
[14] McCorduck P., Cfe C. *Machines Who Think: A Personal Inquiry into the History and Prospects of Artificial Intelligence*. CRC Press; Boca Raton, FL, USA: 2004. [Google Scholar]
[15] Alpaydin E. *Introduction to Machine Learning*. MIT Press; Cambridge, MA, USA: 2020. [Google Scholar]
[16] Brynjolfsson E., McAfee A. *The Second Machine Age: Work, Progress, and Prosperity in a Time of Brilliant Technologies*. WW Norton & Company; New York, NY, USA: 2014. [Google Scholar]
[17] Russell S.J., Norvig P. *Artificial Intelligence a Modern Approach*. Pearson; London, UK: 2010. [Google Scholar]
[18] LeCun Y., Bengio Y., Hinton G. Deep learning. *Nature*. 2015;521:436–444. doi: 10.1038/nature14539. [PubMed] [CrossRef] [Google Scholar]
[19] Wang F., Preininger A. AI in health: State of the art, challenges, and future directions. *Yearb. Med. Inform.* 2019;28:16–26. doi: 10.1055/s-0039-1677908. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
[20] DuBois K.N. Deep medicine: How artificial intelligence can make healthcare human again. *Perspect. Sci. Christ. Faith.* 2019;71:199–201. [Google Scholar]
[21] Kaur S., Singla J., Nkenyereye L., Jha S., Prashar D., Joshi G.P., El-Sappagh S., Islam M.S., Islam S.R. Medical diagnostic systems using artificial intelligence (ai) algorithms: Principles and perspectives. *IEEE Access*. 2020;8:228049–228069. doi: 10.1109/ACCESS.2020.3042273. [CrossRef] [Google Scholar]
[22] Cortez N. *Digital Health: Scaling Healthcare to the World*. Springer; Cham, Switzerland: 2018. pp. 249–269. [Google Scholar]
[23] Acharya YT, Sushruta Samhita of Sushruta, Nibandha Sangraha, Uttara Tantra: Ver. Ed 4.9 th Ch 58 Varanasi: Chaukhamba Surbharati Prakashana 2009; 787.
[24] Samhita AC, English translation by Sharma RK and Dash B: Siddhi sthan (9:46), Chaukhambha Sanskrit series office, Varanasi 2010; 2.
[25] Agnivesha. Charaka samhita, English translation by Sharma RK, Dash B. Siddhi sthan (9:36), Chaukhambha Sanskrit series office, Varanasi 2010; 2.
[26] Vagabhata's Astanga Hrydaya, English translation by Murthy PKRS: Nidanasthana, ch-9 Mutraghata Nidana, shlok-23-24 Edition- Reprint Published by Chowkhamba Krishnadas Academy, Varanasi 2012; 2: 88.
[27] Sushruta. Sushruta samhita, English translation by Sharma Uttar Tantra (58:7-8). Chaukhambha Vishvabharati Varanasi 2010; 3: 5.
[28] Samhita SS, English translation by Sharma PV, Uttar Tantra (58:18-19), Chaukhambha Vishvabharati , Varanasi 2010; 3:
[29] Ibidem (16), Ch. Si. 9/42-43;719 & As. Hr. Ni. 9/33-34, 367
[30] Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005;7 Suppl 9(Suppl 9):S3-S14. [PMC free article] [PubMed]

[31] Abrams P. LUTS, Benign Prostatic Hyperplasia, BPE, BPO: A Plea for the Logical Use of Correct Terms. Rev Urol. 1999 Spring;1(2):65. [PMC free article] [PubMed]
[32] Silverman WM. "Alphabet soup" and the prostate: LUTS, Benign Prostatic Hyperplasia, BPE, and BOO. J Am Osteopath Assoc. 2004 Feb;104(2 Suppl 2):S1-4. [PubMed]
[33] Abrams P. New words for old: lower urinary tract symptoms for "prostatism". BMJ. 1994 Apr 09;308(6934):929-30. [PMC free article] [PubMed]
[34] Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S11-8. [PubMed]
[35] Parsons JK. Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors. Curr Bladder Dysfunct Rep. 2010 Dec;5(4):212-218. [PMC free article] [PubMed]
[36] Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, Woo HH, Te AE, Kaplan SA. Benign prostatic hyperplasia. Nat Rev Dis Primers. 2016 May 05;2:16031. [PubMed]
[37] Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984 Sep;132(3):474-9. [PubMed]
[38] Loeb S, Kettermann A, Carter HB, Ferrucci L, Metter EJ, Walsh PC. Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging. J Urol. 2009 Oct;182(4):1458-62. [PMC free article] [PubMed]
[39] Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol. 2005 Apr;173(4):1256-61. [PubMed]
[40] Kupelian V, Wei JT, O'Leary MP, Kusek JW, Litman HJ, Link CL, McKinlay JB., BACH Survery Investigators. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med. 2006 Nov 27;166(21):2381-7. [PubMed]
[41] Parsons JK, Bergstrom J, Silberstein J, Barrett-Connor E. Prevalence and characteristics of lower urinary tract symptoms in men aged > or = 80 years. Urology. 2008 Aug;72(2):318-21. [PMC free article] [PubMed]
[42] Stroup SP, Palazzi-Churas K, Kopp RP, Parsons JK. Trends in adverse events of benign prostatic hyperplasia (Benign Prostatic Hyperplasia) in the USA, 1998 to 2008. BJU Int. 2012 Jan;109(1):84-7. [PubMed]
[43] Centers for Disease Control and Prevention (CDC). Trends in aging--United States and worldwide. MMWR Morb Mortal Wkly Rep. 2003 Feb 14;52(6):101-4, 106. [PubMed]
[44] Jin B, Turner L, Zhou Z, Zhou EL, Handelsman DJ. Ethnicity and migration as determinants of human prostate size. J Clin Endocrinol Metab. 1999 Oct;84(10):3613-9. [PubMed]
[45] Ganpule AP, Desai MR, Desai MM, Wani KD, Bapat SD. Natural history of lower urinary tract symptoms: preliminary report from a community-based Indian study. BJU Int. 2004 Aug;94(3):332-4. [PubMed]
[46] Johnson, K. W., et al. "Artificial intelligence in healthcare: opportunities and challenges." *American Journal of Managed Care* 24.19 (2018): 466-472.
[47] Esteva, A., et al. "A guide to deep learning in healthcare." *Nature Medicine* 25.1 (2019): 24-29.
[48] Yu, K. H., Beam, A. L., and Kohane, I. S. "Artificial intelligence in healthcare." *Nature Biomedical Engineering* 2.10 (2018): 719-731.
[49] Sutton, R. T., et al. "An overview of clinical decision support systems: benefits, risks, and strategies for success." *NPJ Digital Medicine* 3.1 (2020): 17.
[50] Holzinger, A., et al. "What do we need to build explainable AI systems for the medical domain?" *arXiv preprint arXiv:1712.09923* (2017).
[51] Topol, E. J. "High-performance medicine: the convergence of human and artificial intelligence." *Nature Medicine* 25.1 (2019): 44-56.
[52] Tiwari, A. K., et al. "Ayurveda and traditional Chinese medicine: a comparative overview." *Current Science* 96.6 (2009): 793-797.
[53] Shortliffe, E. H., and Sepúlveda, M. J. "Clinical decision support in the era of artificial intelligence." *JAMA* 320.21 (2018): 2199-2200.
[54] Dilsizian, S. E., and Siegel, E. L. "Artificial intelligence in medicine and cardiac imaging: harnessing big data and advanced computing to provide personalized medical diagnosis and treatment." *Current Cardiology Reports* 16.1 (2014): 441.